News
GSK hopeful of a 'blockbuster' cancer drug after promising trial results
Mo-Rez shrank or eliminated tumours in 62 percent patients with ovarian cancer, and in 67 percent of those with endometrial cancer
Apr 14, 2026
This Site is Intended for Healthcare Professionals Only